Welcome, Guest. Please login or register.
November 02, 2024, 01:21:47 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 265
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 209
Total: 209

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: High Take-Two Cure Rates With Gilead’s New Triple-Drug Hep C Regimen  (Read 6010 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Gilead’s experimental fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir cured hepatitis C virus (HCV) at high rates among those who failed a previous treatment for the virus in two recent large trials, MedPage Today reports. The regimen also performed very well among participants with compensated cirrhosis, the less severe stage of the advanced liver disease, which can lower the chance of a cure.

At the end of June, the FDA is expected to decide whether to approve the combination tablet of the NS5B polymerase inhibitor sofosbuvir (brand name Sovaldi), the NS5A inhibitor velpatasvir (when combined with sofosbuvir, this drug is marketed as Epclusa) and the NS3-NS4A protease inhibitor voxilaprevir.

Read more...
https://www.hepmag.com/article/high-taketwo-cure-rates-gileads-new-tripledrug-hep-c-regimen

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.